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ABSTRACT
This paper, originated as a submission (now updated) to the U.K. Medicines Control Agency
and Committee of Safety of Medicines (CSM) on January 11, 2002, in response to a report circu-
lated by the German Federal Institute for Drugs and Medical Products (German initials are BfArM),
a compilation of which is summarized in Appendix 2. This agency issued notification in late No-
vember 2001 of some thirty adverse events associated with the use of concentrated standardized
preparations of kava (Piper methysticum, Forst. f.) reported from Germany and Switzerland. An
analysis of the summary of the BfArM case reports (see Appendix 2) shows that these contain du-
plications among the cases cited. The original submission that was sent to the CSM January 2002
has been updated to the version published here. This new version was completed in April 2002.
As a result of the alert from BfArM, the evaluation of kava’s safety is now occurring on a
worldwide basis and, being that this a matter of considerable importance to the public, the health
care community, and regulatory authorities as well as to kava farmers throughout Polynesia, it
is it important to depict this progress report. As such, this updated report does not provide fi-
nal answers. The material released by the BfArM is lacking in detail; however, it is hoped that
this report will shed light on the kava controversy. It is anticipated that there will be further up-
dates shortly.
This report, prepared on behalf of the Traditional Medicines Evaluation Committee, a subcom-
mittee of the European Herbal Practitioners Association, argues that many of the adverse events
cited by the BfArM should not be attributed to kava. In addition, the report states that the prop-
erties of concentrated standardized kava extracts—as opposed to preparations that closely ap-
proximate those created for traditional use—contribute to causing adverse events. This report pro-
poses a number of simple measures that will ensure that safe kava preparations may continue to
be available in the United Kingdom.
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BENEFITS OF KAVA
Kava (Piper methysticum, Forst. f.) is an im-portant herbal medicine with unique
properties. The ability of herbal practitioners to
care for their patients would be significantly af-
fected if this herb’s use were restricted or cur-
tailed so that practitioners were unable to pre-
scribe it. Since the early 1900s, kava has been
used in Britain by herbal practitioners, mainly
1University of Central Lancashire, Preston, United Kingdom.
2Midsummer Cottage Clinic, Oxon, United Kingdom.
3University of Westminster, London, United Kingdom.
for urinary problems (Ellingwood, 1919). The
indications given in the British Herbal Pharma-
copoeia (Anonymous, 1983) are “Cystitis, Ure-
thritis, Rheumatism, and Infection of the gen-
ito-urinary tract.” More recent texts emphasize
the herb’s usage as a nervine. For example, in-
dications given by Mills and Bone (2000) are
“anxiety of nervous origin, nervous tension,
restlessness or mild depression of non-psy-
chotic origin, menopausal symptoms and in-
flammation and infections of the genitourinary
tracts of both men and women; muscular and
nervous pain; and insomnia.” Kava use as a
nervine (which is its traditional therapeutic
use) has increased markedly in recent years
partly because of the evidence for clinical effec-
tiveness found in clinical trials (Pittler and Ernst,
2000). However, it is interesting to note that
such usage is not completely new. Felter (1905)
notes kava’s application, inter alia, for treating
neuralgia, dizziness, and despondency. The
herb has a particular value for treating agita-
tion and anxiety (Spinella, 2001) when other
nervines have proved to be ineffective.
Clinical trials have been reviewed recently
by Pittler and Ernst (2000) who stated that, 
for treating anxiety, kava’s superiority over
placebo was suggested by all seven trials un-
der review and that, for the three trials in-
cluded in the meta-analysis, there was a sig-
nificant reduction in score on the Hamilton
Anxiety Scale. The clinical trials were all car-
ried out in Germany where kava is prescribed
by physicians and sold over the counter in
pharmacies for treating anxiety and insomnia.
A recent review (Loew, 2002) listed nine dou-
ble-blinded, randomized controlled trials, in-
volving 808 patients, and stated that kava was
significantly superior to placebo for treating
symptoms associated with anxiety. These trials
used a range of products standardized on
15%–70% kavalactones, providing a daily
dosage of 60–210 mg per day of kavalactones.
The use of kava is being increasingly advocated
as an alternative to benzodiazepines for treat-
ing anxiety and has been tested in at least one
trial. (Loew, 2002). The trial was 28 days long
and involved 61 people. And, for example, De
Leo et al. (2001) showed a significant relative
decrease in anxiety in a double-blinded ran-
domized trial on 40 menopausal women when
kava was combined with hormone replacement
therapy. This trial lasted for 6 months and the
dosage of kava extract was 100 mg per day (con-
taining 55 mg of kavain). It has been claimed that
the German Federal Institute for Drugs and Med-
ical Products, (German initials are BfArM), cited
doubts about kava’s efficacy for treating anxiety
as one reason for starting an investigation on the
herb (Anonymous, 2001). Surprise was ex-
pressed in Germany for this reason because it
was claimed (Anonymous, 2001) that a recent
randomized controlled trial awaiting publication
had demonstrated kava’s efficacy for this use at
doses that conform to the Commission E mono-
graph on the herb (Blumenthal, 2000).
The modern use of kava as a nervine is in ac-
cordance with its traditional usage in the South
Pacific. Kava drinkers report a sense of relax-
ation and tranquillity and manifest a sociable
attitude (Chanwai, 2000). The herb is used as a
social and ceremonial drink among men in
Polynesia. In modern times, as the influence of
the Christian missionaries decreases, kava’s
use has become more widespread and fre-
quent. For instance, Kava is an important part
of social life in Fiji. Fijian spiritual leaders are
called dauvaguna, the literal translation of
which means “expert at drinking kava.”
(Greenwood-Robinson, 1999). Kava is not ad-
dictive and does not seem to produce the vio-
lent antisocial effects that alcohol produces
(Lebot et al., 1997). However, there are serious
concerns in Australia (Clough, et al., 2000)
about the herb’s abuse as a recreational drug
when it is used to excess. It has been associated
with inactivity, confusional states, and general
ill-health, possibly as a result of associated mal-
nutrition caused by irregular eating habits
(Chanwai, 2000). In Aboriginal communities
malnutrition is not uncommon and this associ-
ation is considered to be unproven.
WHAT IS KAVA?
Root bark and root of kava are used, either
fresh or dried, for its preparation.
Based on an archaeological study of charac-
teristic drinking bowls, it has been proposed
that the herb was first domesticated in Polyne-
sia more than 2000 years ago (Green, 1974 [cited
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in Lebot et al., 1997]). A comprehensive survey
by Lebot and Levesque in 1989 (cited in Lebot
et al., 1997) suggests that kava was originally
domesticated in the Vanuatu islands.
Kava is now obtained from a wide range of
cultivars in the South Pacific. The plant is al-
ways propagated vegetatively from stem cut-
tings as it does not reproduce via fertilization
methods. There are many cultivars and new
strains continue to be developed by Polynesian
farmers because each strain is considered to
have different psychoactive effects.
In recent years, there has been increasing
pressure on the market because of the increased
worldwide demand for kava. In 1998, it was
among the top-selling herbs in the United
States, with a turnover of $8 million, repre-
senting a growth rate of 473% (Pittler and Ernst,
2000). It is possible that the current hepatotox-
ity problems are, to some extent, a consequence
of poor quality control caused by a rapid and
extraordinary increase in the size of the market
(Murray, 2000).
There are also concerns that intensive culti-
vation and harvesting may affect the quality of
the product (Aarlbersberg, 1999). However be-
ing that a range of products is implicated, this
is unlikely to provide a satisfactory explanation
for all the reported adverse reactions. It is
hoped that the BfArM will release relevant data
about the source and quality assurance of the
kava supply in due course.
KAVA PHARMACOLOGY
Kava is a well-researched herb. The crys-
talline resin was first isolated in 1857 by a
French naval pharmacist and a detailed mono-
graph was published in 1886 (Lewin, 1886
[cited by Lebot et al., 1997]). The kavalactones
are considered to be the active constituents and
have been shown in animal studies to have a
sedative action (Hansel, 1996), although the
mechanism is unclear (Spinella, 2001). The
kavalactones are found in the resinous portion
(5%–9%) of the plant material and are poorly
soluble in water.
Kavalactones are 4-methoxy-2-pyrones with
phenyl or styryl substituents at the 6th position
(Lebot et al., 1997). Total kavalactone content
varies from 3% to 20% dry weight. Eighteen lac-
tones have, so far, been isolated (He et al., 1997)
with the following six compounds (including
four chiral enantiomers and two achiral enan-
tiomers) being considered most important
(Haberlain, 1997; see Fig 1):
 Chiral enantiomers:
(1) (1)-kavain
(2) (1)-dihydrokavain
(3) (1)-methysticin
(4) (1)-dihydromethysticin
 Achiral enantiomers:
(5) yangonin
(6) demethoxyangonin.
TRADITIONAL 
PREPARATION TECHNIQUES
Kava is traditionally prepared in the South
Pacific by grinding and mixing the root or root
bark with cold water. This makes an emulsion
that is a suspension of the resinous constituents
in water (Lebot et al., 1997). The herb is also
prepared as an emulsion (also traditionally
prepared without heating) in coconut milk
(Johnson, 1999). The efficiency of extraction of
the active constituents, which is measured by
kavalactone extraction into water, varies con-
siderably (Murray, 2000) but is higher from
fresh material than from the dried plant. Kava
consumed in Vanuatu is reputed to be the
strongest anywhere in the South Pacific. The is-
lands of Tanna and Pentecost are especially
noted for their potent brews. It is thought that
part of this increase in potency is the result of
preparing the drink from the raw fresh roots,
whereas in Fiji and elsewhere, it is made from
dried rootstock (Greenwood-Robinson, 1999).
MODERN PREPARATION TECHNIQUES
The bioavailability of kava constituents
varies substantially, depending on the method
of extraction (Hansel et al., 1994 [cited in Schulz
et al., 1997]; Loew, 2002). Kava is predomi-
nantly available in Germany as a so-called con-
centrated standardized extract that is designed
to maximize extraction of the kavalactones.
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Schulz noted that, to create these concentrated
standardized extracts, kava is dissolved in a
high percentage of an ethanol–water mixture
to obtain extracts containing approximately
30% kavalactones or, alternatively, using an
acetone–water mixture to obtain extracts con-
taining approximately 70% kavalactones. Whit-
ton, Whitehouse, and Evans (Appendix 1)
make the same point about enhanced kavalac-
tone extraction using a high ethanol or acetone
medium but detail somewhat different extrac-
tion values. Both types of products have a herb-
to-extract ratio of approximately 12–20:1
(Schulz, 1997). The dosage recommended by the
German Commission E is expressed as the
equivalent of 60–120 mg of kavalactones per day
(Blumenthal, 1998).
The preparation methods used for stan-
dardized products are highly technical and 
extraction rates vary (Kubatova, et al., 2001)
depending on the solvents used and the tem-
perature at which the products are prepared.
As Whitton et al. propose (Appendix 1), both
efficacy and safety may depend on the
kavalactones remaining in their natural forms
and on the extraction of the other natural con-
stituents of the plant.
Varying extraction techniques and preparation
methods may result in an unnatural variation in
the relative concentration of each lactone or in
production artifacts that may be pathologic to the
liver. It should be noted that some commercial
kava products may also contain synthetic
racemic kavain that may have other characteris-
tics than the naturally occurring product has. It
is clear that these technical matters related to ex-
traction techniques require further elucidation.
Proponents of concentrated standardized
products assert that they provide an effective
dose within a consistent range. The traditional
water-based kava preparations of the Polyne-
sian peoples and low-alcohol kava tinctures
used by herbal practitioners have been consid-
ered to be unreliable because the concentration
of active constituents is relatively low and
varies from kava batch to batch. However,
there are four relevant counterarguments:
(1) The whole range of the constituents may
produce a more effective and safe medicine
(Williamson, 2001).
(2) Some constituents, not necessarily consid-
ered active, may enhance the safety of the
medicine (Appendix 1).
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FIG. 1. Kavapyrones of kava (Piper methysticum). Per Haberlein et al., 1997.
(3) Definitive isolation of the active constituent
is elusive in other medicinal plants, such as
Hypericum perforatum (McIntyre, 2000;
Barnes et al., 2001).
(4) Herbal practitioners rely on the synergy be-
tween a whole range of constituents in the
herb or herb within a herbal prescription,
which is individually prescribed for a pa-
tient. This positive interaction may also
have the benefit of keeping levels of any
one constituent below the safety threshold.
LOW-ALCOHOL TINCTURES 
The Traditional Medicines Evaluation Com-
mittee (TMEC) strongly advocates the use of
extraction techniques that closely approximate
those traditionally used in Polynesia. This
would require the use of low-alcohol tinctures
made by the traditional cold maceration
processes common to U.K. tincture making.
The reasons for this opinion are set out below;
they have also been explored by Whitton et al.
(Appendix 1).
Tinctures used by herbal practitioners are
prepared by macerating dried kava in a mix-
ture of water and ethanol. It has been shown
that such extracts using 25% ethanol/75% wa-
ter contain up to 30 times fewer kavalactones
than the concentrated standardized prepara-
tions (Appendix 1). The traditional preparation
method, using a mixture of 25% ethanol/75%
water, extracts a wider range of the natural
kava constituents, (Appendix 1).
DOSAGE AND OVERDOSAGE
Assuming a 1:5 25% tincture and an upper
limit of 20% kavalactones in the dried herb
(concentrations stated as 3%–20%; see section
on Pharmacology below), then 500 mL of the
herb would contain (100 3 0.2 3 0.15) 5 3 g
(3000 mg) of kavalactones. In addition, assum-
ing a daily dosage of 5–10 mL of the 1:5 25%
tincture, the daily dose of kavalactones
amounts to a maximum of 30–60 mg. If the con-
centration of kavalactones were lower, for ex-
ample at approximately 10%, as appears to be
the case with regard to Australian kava dis-
cussed by Clough et al. (2000), then this dosage
falls to 15–30 mg per day. It is noteworthy that
the maximum daily dosage here is equivalent
to the minimum daily dosages of the 60–210
mg kavalactones given in clinical trials of kava
conducted in Germany.
Although standardized extracts provide a
higher dosage of kavalactones than low-alco-
hol tinctures, overdosage in itself is unlikely
to be the cause of hepatotoxicity. Strong evi-
dence for this is the fact that kava is taken
daily at high doses as a normal part of daily
life in large areas of the South Pacific. Indeed,
some of the accounts of high kava intake are
remarkable. For example Chanwai (2000) de-
scribed the case of a man who was admitted
to a hospital after an overdose but “slept off”
his symptoms and admitted to consuming up
to 40 bowls of a kava preparation per day for
the last 14 years. In Australia, missionaries in-
troduced kava to the aborigines in the 1980s
as a substitute for alcohol and it is claimed that
this has led to abuse of kava. Clough et al.
(2000) discussed this concern and reviewed
twelve studies on the amount of kava used.
The researchers found that social setting ap-
pears to determine the amount used, with lone
drinkers consuming much more than people
who enjoy kava in a family group. The re-
searchers described normal use of kava in the
Northern Territory as being 37 g of kava pow-
der (containing approximately 3800 mg of
kavalactones) per hour with heavy consumers
using approximately 610 g per week, prepared
as a drink. The incidence of serious illness re-
sulting from hepatotoxicity associated with
regular kava usage would surely have been
observed by the medical services in Polynesia
and Australia if overdosage of kavalactones
were the main cause of hepatotoxicity.
UNTOWARD EFFECTS
There is a justified concern in Europe that
idiosyncratic hepatotoxicity associated with us-
ing some herbal medicines may not be identi-
fied because the population that takes herbal
medicines is not large enough to produce suf-
ficient cases for the association to be noted. But
the fact that kava remains in traditional usage
to such a wide extent is a powerful argument
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that idiosyncratic hepatotoxicity would have
been noted.
Two postmarketing observation studies in
Germany each on more than 3000 people were
cited by Pittler and Ernst (2000) in addition to
the abovementioned clinical trials. In these ob-
servational studies, the rate of adverse events
was 2.3% (with a daily dose of 120–240 mg of
kavalactones) and 1.5% (with a daily dose of
105 mg of kavalactones). The most frequent ad-
verse reports were gastrointestinal complaints,
allergic skin reactions, headaches, and photo-
sensitivity.
There is evidence in the South Pacific of a char-
acteristic kava-induced skin disease, a scaly rash
that is suggestive of icthyosis—a condition called
“kava dermopathy” (Ruze, 1990). Although the
skin becomes yellow, the description does not
suggest an underlying hepatic condition in that
the patient remains well, the rash is not itchy,
and the condition is ameliorated without treat-
ment if heavy use of kava is reduced.
The German and Swiss reports cited by the
BfArM are of concern because there have been
previous reports of hepatotoxicity associated
with the use of some medicinal plants (Larrey,
1997). The kava case reports from the BfArM
(see Appendix 2) include all three of the main
forms of acute damage that can result from ad-
verse drug reactions: (1) necrosis; (2) drug-in-
duced hepatitis; and (3) cholestatic hepatitis
(Hodgson and Levi, 1997). This suggests that
there is a range of causes rather than just one
cause in these cases. The BfArM case reports
have been circulated worldwide and are cur-
rently being evaluated by government agencies
in Europe, Australia, Canada, the United
States, and elsewhere. We have received a
number of informal case assessments from
these sources that cannot be specifically cited
because of their confidential status. To achieve
transparency and encourage a full debate about
kava, however, the BfArM cases are evaluated
in the section entitled Discussion of Cases Re-
ported by the BfArM.
CRITERIA FOR ASSESSING THE 
CASE REPORTS
A recent review of the information available
on the case reports (Schmidt and Nahrstedt,
2002) is supported by details of the case re-
ports on the Web site of the University of
Muenster (www.uni-muenster.de/chemie/pb/
kava/analyse.html)
The criteria for causality assessment of ad-
verse reactions used are as follows (Edwards
and Aronson, 2000):
Probable is defined as:
 A clinical event, including a laboratory test
abnormality, that occurs in a plausible time
relation to drug administration and that can-
not be explained by coincidental or concur-
rent disease or other drugs or chemicals
 The response to withdrawal of the drug
(dechallange) should be clinically plausible
 The event must be definitive, pharmacolog-
ically or phenomenologically, using a satis-
factory rechallenge procedure if necessary.
Possible is defined as:
 A clinical event, including a laboratory test
abnormality, with a reasonable time relation
to administration of the drug but that could
be explained by concurrent disease or other
drugs or chemicals
 Information on drug withdrawal may be
lacking or unclear.
Unlikely is defined as:
 A clinical event, including a laboratory test
abnormality, with a temporal relation to the
administration of the drug, which makes a
causal relation improbable, and in which
other drugs, chemicals, or underlying dis-
ease provide plausible explanations.
Unassessable is defined as:
 A report suggesting an adverse reaction that
cannot be judged because information is in-
sufficient or contradictory and cannot be
supplemented or verified.
DISCUSSION OF CASES REPORTED 
BY THE BfArM
The cases discussed below are analyzed and
categorized by common factors of note, with
our own assessments.
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(1) Cases of most concern
This group includes five cases: 10; 13; 16; 18;
and 28. According to the assessments made 
by various government agencies, these cases
cause the most concern and are often cited as
being probable. For this reason, these cases are
dealt with first. As discussed below, most—if
not all—of these cases have associated factors
that put this probable categorization into ques-
tion.
Case 10. This case described necrotizing hep-
atitis in a 39-year old female patient with pos-
itive reexposure (Strahl, et al., 1998). During the
first period that the kava product was taken,
an oral contraceptive and paroxetine were con-
comitant medications. It appears that paroxe-
tine was not the only antidepressant taken by
this patient who also occasionally took St.
John’s wort (Hypericum perforatum). The Exec-
utive Summary issued by the Bundesverband
der Arzneimittel Hersteller e.V. (BAH) and
Bundesverband der Pharmazeutischen Indus-
trie e.V. (BP) (see Appendix 3) stated: “A causal
relationship with kava cannot be excluded, but
the patient’s history and a potential preexisting
liver damage must be taken into account. In ad-
dition, the kava preparation used was not iden-
tified by the physician.”
Moreover, in this case, taking paroxetine in
combination with an oral contraceptive may
well have led to overburdening the liver, a sit-
uation that could have been exacerbated by tak-
ing a kava preparation. Schmidt and Nahrstedt
(2002) suggested that this case may be associ-
ated with an immunologic reaction. After re-
viewing all of the cases in detail, Schmidt and
Nahrstedt (2002) concluded that this is the only
case for which there was sufficient information
to make an association with kava appear prob-
able and for which the dose of kava also con-
formed to that recommended by the Com-
mission E monograph (Blumenthal, 2000).
However, as discussed below, Russmann et al.
(2001) tested this patient for CYP2D6 and, as in
Case 16, found this patient to be CYP2D6 defi-
cient, which appears to have made her partic-
ularly vulnerable to the cocktail of drugs she
was taking. Given the complicating features of
this case, we submit that this case should be
classed as possible rather than probable.
Case 13. This was a case of a 62-year-old
woman with jaundice. The BfArM table (see
Appendix 2) noted, regarding concomitant
medication, that there was “none denoted” but
it was claimed that concomitant medication did
exist but was “unknown.” The insufficiency of
data provided for this case was highlighted by
BfArM’s warning note: “No medical message!”
In addition, it should be noted that no details
of the dosage of kava or period of its adminis-
tration were apparently recorded for this case.
This is clearly insufficient information on
which to base a probable assessment.
Case 16. This case concerned a 33-year-old
woman with jaundice. The woman was
recorded as having taken an overdose of alco-
hol measured at 60 g (Russman et al., 2001) and
then analgesics, including paracetamol, fol-
lowing this alcohol binge. Despite the massive
intake of alcohol, a liver biopsy indicated that
a drug rather than an alcohol induced toxic
genesis. However, this case, like that of Case 10
above, was discussed by Russman et al. (2001),
who demonstrated afterward that this patient
was shown to be CYP2D6 deficient which (as
discussed below) seems to be a risk factor for
the hepatotoxicity that was ascribed to kava.
We submit that, given these circumstances, this
case should be considered possible rather than
probable.
Case 18. This case concerned a 50-year-old
man who had necrosis leading to a liver trans-
plant. This patient took a product manufac-
tured by acetone extraction at a dose deliver-
ing 210–280 mg of kavalactones per day for 1.5
months, “moderate alcohol” (“moderate” is not
defined by BfArM), evening primrose
(Oenothera biennis), and a yeast preparation.
The dosage of kava was well above the Ger-
man Commission E recommended dose of
kavalactones (Blumenthal, 1998). It was also
recorded that 500–1000 mg of paracetamol was
taken by this patient shortly before transplan-
tation. The combination of paracetamol and al-
cohol plus the very high dose of kava extracted
in acetone taken by this man casts serious
doubts on the assessment of probable in this
case.
Case 28. (BAH) This case concerned a
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woman, age unknown, with hepatitis. This case
is hard to assess because neither the patient’s
age nor diagnosis was given and the woman
was taking eleven medications, including estra-
diol valerate, acetylcysteine, losartan (which is
rarely be associated with hepatitis), and mepra-
zole (which can be associated with liver disease
although this is rare). Omeprazole is metabo-
lized by the polymorphic CYP2C19, which is 
absent in 3% of Caucasians (Flockhart et al.,
2000). The woman was also taking echinacea
(Echinacea purpurea) and five products that ap-
peared to be for upper respiratory problems. It
should be noted that this patient was taking syn-
thetic kavain not kava. A comment from BfArM
concerning this case noted “recurrence of the he-
patic side-effects,” which has evidently been in-
terpreted by some authorities as being equiva-
lent to a “positive rechallenge.” Whether or not
this was actually so was not clear from the data
supplied. It appears (Schmidt and Nahrstedt,
2002) that Case 28 has been published as two
cases with slightly different details. This is con-
fusing, and considering that the woman was tak-
ing 11 other medications together with a syn-
thetic kava (which, we submit, is not equivalent
to natural kava) and that no diagnosis of her
condition was supplied, this calls the assessment
of probable in this case into question.
(2) Cases associated with taking synthetic kavain
In this category there were 4 cases: 1; 2; 19;
and 28.
In each of these cases, the patients concerned
were taking a product made from synthetic
kavain. Although, the outcome was hepatitis in
all four cases, kavain cannot be equated with
the naturally occurring form of kava, which
contains many other constituents that may play
an important role in ensuring the safety of this
herb. Therefore, we submit that no inference
should be drawn from these cases. Traditional
usage should not be taken as evidence for safe
usage of synthetic products.
(3) Patients who were taking oral contraceptive
pills or hormone replacement therapy (HRT)
together with drugs that can also be associated
with liver damage
The cases in this category were: 4; 10; 12; 20;
21; and 28.
Cholestatic jaundice associated with use of
estrogen-containing medications is extremely
rare (Lindberg, 1992) but does occur. In these
6 cases, the women were also taking drugs that
can also be associated with jaundice.
Case 4. This case involved a 39-year-old
woman with jaundice. She was on diazepam,
10 mg, PRN, for 6 months. Some authorities
called this case possible. Our assessment is that
the case is unassessable.
Case 10. This case involved a 39-year-old
woman with necrotizing hepatitis. For a de-
tailed assessment, see above.
Case 12. This case involved a 37-year-old
woman with hepatitis. She was on 150 mg of
diclofenac via intramuscular injection. Hepato-
toxic reactions associated with nonsteroidal
anti-inflammatory drug use are extremely rare
and concomitant exposure to other hepatotoxic
drugs is considered to be an important factor
(Bareille et al., 2001). This case of hepatitis is
difficult to interpret because it occurred in
Brazil and because “reexposure was said to be
negative for all three drugs.” We regard this
case as unassessable .
Case 20. This case involved 50-year-old
woman with necrosis, who had a liver trans-
plant. She had a 20-year history of combined
oral contraceptive use but had changed months
earlier to estradiol valerate (which was appar-
ently taken alone) as HRT. She had also started
glimepiride 8 months earlier. This is used for
treating type II diabetes and is rarely associated
with cholestatic jaundice and liver failure. We
regard this case as unlikely.
Case 21. This case involved a 22-year-old
woman with necrosis, who had a liver trans-
plant. This woman had changed from Valette
(Jenapharm GmbH, Jena, Germany) (2 mg of
dienogest and 0.03 mg of ethinlestradiol) to
Pramino (180/215/250 mcg of norgestimate
and mcg 25 of ethinylestradiol). She also took
rizatriptan, if required, for migraine relief.
Rizatriptan should be used with caution in he-
patic impairment and avoided if a patient has
severe liver disease. Some authorities consider
this case as being possible but our assessment
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is, in view of the other medications taken, is
that this case is unassessable .
Case 28. This case involved a woman, age un-
known, with hepatitis. This case is discussed at
length above. As noted above, this patient was
taking synthetic kavain not kava.
(4) Patients who were taking drugs that can be
associated with liver damage
There were ten cases in this category: 1; 6; 9;
14; 15; 17; 19; 23; 26/27; and 29.
Case 1. This case involved a woman, age 69,
with cholestatic hepatitis. She was taking pen-
toxifylline (which can be associated with intra-
hepatic cholestasis) and a diuretic including the
potassium-sparing triamterene (which can be
associated with jaundice). As noted above, this
patient was taking synthetic kavain not kava.
We consider this case unassessable.
Case 6. This case involved a woman, age 50,
with hepatitis. She was taking frusemide
(which can be associated with cholestatic jaun-
dice), triamterene, atenolol, and a large dose of
terfenadine (300 mg). The recommended dose
of terfenadine in the British National Formu-
lary (March 2001) is 60–120 mg. The Formulary
recommends avoiding this drug in patients
who have hepatic impairment and also says to
“avoid concomitant administration of drugs li-
able to produce electrolyte imbalance such as
diuretics” (British National Formulary, 2001).
Despite this warning, this woman was also tak-
ing the diuretic frusemide. The Interkantonalen
Kontrollstelle der Schweiz of Switzerland con-
sidered this case of hepatitis to be caused by
terfenadine. And, although some authorities
regard this case as possible, our assessment is
that this case is unlikely.
Case 9. This case involved an 81-year-old
woman who had liver failure and subsequent
death. She was taking hydrochlorothiazide
(which can occasionally be associated with in-
trahepatic cholestasis). However, according to
Schmidt and Nahrstedt (2002), there was evi-
dence of chronic alcohol abuse and they re-
ported that the autopsy showed chronic pan-
creatitis that was characteristic of alcohol
abuse. The autopsy report (Schmidt and
Nahrstedt, 2002) apparently said that the
symptoms must have occurred over a period
of at least 18 months. The report conceded that
“hepatic impairment by alcohol [was] not ex-
cluded.” In these circumstances, it seems en-
tirely reasonable to claim that this case is un-
related to kava use. We regard this case as
unlikely.
Case 14. This case involved a 33-year-old
woman with hepatitis. Cisapride may have
been taken (which can cause reversible changes
that show in liver-function tests). Cirrhosis in
a woman of 33 is an unexplained finding and
the detail in this case is inadequate to elucidate
it. We consider this case to be unassessable.
Case 15. This case involved a 46-year-old
woman with jaundice. She had been taking hy-
drochlorothiazide (which can be associated
with intrahepatic cholestasis) for 5.5 months
plus 80 mg of valsartan and 80 mg of
propanolol per day. Some authorities regard
this case as possible but we consider it to be
unassessable .
Case 17. This case involved a 59-year-old
woman with jaundice. She had taken 100–200
mg of celecoxib, a cyclo-oxygenase-2 inhibitor,
per day. According to the criteria for causality
assessment of adverse reactions, some author-
ities consider this case to be possible but our as-
sessment is that it is unassessable .
Case 19. This case involved a 21-year-old
woman with hepatitis. She was taking panto-
prazole (which, as with omeprazole, can be as-
sociated with liver disease). She was also taking
paracetamol and metoclopramide and had over-
dosed on kavain. More detail is needed on other
medical conditions suffered by this patient in or-
der to interpret this case. It is suggested by
Schmidt* that this woman was using up to 10
tablets per day of the product (the recom-
mended dose is up to 6 tablets per day) and that
there was apparently a discussion in her med-
ical record file that she may also have used Ec-
stasy (substance that has been associated with
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*Personal communication from M. McGuffin to M. McIn-
tyre; available as an online document at ehpa@globalnet.
co.uk
fulminant hepatic failure). This case appears to
be unassessable .
Case 23. This case involved a 35-year-old
woman with jaundice. According to the BfArM
(see Appendix 2), this patient also took parac-
etamol but no dosage or details were provided.
This case, and case 25 in the BfArM listing, ap-
pear to be the same case. Both cases have been
labeled as possible by some authorities but,
given the lack of information about the dosage
of paracetamol and the apparent confusion re-
garding cases 23 and 25, we submit that the
only logical assessment is unassessable.
Case 26/27. This case involved a woman who
was either 38 or 39 years’ old with hepatitis. It
appears that the two cases have been duplicated
(Schmidt and Nahrstedt, 2002). The confusion
with this case is another example of inaccurate
data provided by the BfArM. Information re-
garding these cases (or case?), depending on
whether the two reports concern the same
woman, is unclear. Penicillin can be associated
with hypersensitivity and cholestatic jaundice
but the information given is inadequate to make
any meaningful assessment. For this reason, we
class this case as unassessable .
Case 29. This case involved a 60-year-old
woman who had a liver transplant. This woman
was taking piretamide (which is a loop diuretic).
Frusemide, another loop diuretic, can be associ-
ated with cholestatic jaundice. According to the
BfArM chart (see Appendix 2), she was also tak-
ing a sympathomimetic drug, etilefrin. The
dosage of kava varied but was up to 480–1200
mg per day (Schmidt and Nahrstedt, 2002),
which is up to ten times the German Commis-
sion E maximum recommended dose (Blumen-
thal, 1998). Although some authorities have re-
garded this case as possible, in view of the
marked overdosing of kava and the concomitant
medication, this case can hardly be said to be a
reflection on the proper therapeutic use of kava.
(5) Cases in which drugs not associated with
liver damage, herbal medicines, or dietary
supplements or kavain alone were taken
This category had eight cases: 2; 7/8; 11; 13;
22; 24; and 25.
For these cases, detail was limited and the
BfArM did not implicate any other drugs or
medications (although this may not be the
case).
All patients in this group, apart from the pa-
tient in Case 7/8, for whom no information was
given, were reported to have made full recov-
eries. In some of these cases, it is not clear
whether the patients were ill or whether these
cases merely recorded raised liver-function en-
zymes.
Case 2. This case involved a 35-year-old man
with cholestatic hepatitis. Concomitant med-
ication was “unknown.” Apart from Cases 18
and 30, this is the only case for which it is pos-
sible that no other concomitant medication was
taken but there is a marked lack of information
for this case. As noted above, this patient was
taking synthetic kavain not kava. We regard
this case as unassessable .
Case 5. This case involved a woman who was
either 68 or 69 years’ old with cholestatic he-
patitis. She was also taking a St. John’s wort
(Hypericum perforatum) product, which has
been associated with CYP3A4. A biopsy
showed “immunologic hypersensitivity.” This
case may be regarded as possible but, in view
of the immunologic hypersensitivity, it may
well have been an idiosyncratic event that was
not necessarily associated with kava usage.
Case 7/8. This case involved a woman or two
women, ages 72 and/or 75, with cholestatic he-
patitis. These two cases appear to be actually
one case. The woman was taking two
herbal/vitamin products, one of which in-
cluded 0.6 mg of kavalactones. Given the con-
fusion involved, these “cases” must be re-
garded as unassessable .
Case 11. This case involved a 59-year-old
woman who was taking hyoscine butylbro-
mide as a suppository. Schmidt and Nahrstedt
(2002) commented that, according to additional
information obtained from the BfArM, it is un-
certain as to whether this patient was taking a
kava product at all. We regard this case as
unassessable .
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Case 13. This case involved a 62-year-old
woman with jaundice. See above for the dis-
cussion of this case. It does appear that there
was concomitant medication but no details of
this or of the kava dosage are available. This
makes interpretation impossible; consequently,
we regard this case as unassessable .
Case 22. This case involved a 34-year-old
woman with hepatitis. She was taking L-thy-
roxine. No information is available on her vi-
ral serology, differential diagnosis, or alcohol
intake. We regard this case as unassessable .
Case 24. This case involved a 47-year-old
woman who had raised liver-function as
shown on a test. She had a high intake of fish-
oil. The report stated that this patient’s liver en-
zymes returned to normal when she stopped
taking fish oils but, again, the detail is insuffi-
cient. However, this case appears to support
the safe use of kava because report stated that
the patient was “restored to health after dis-
continuation of the concomitant medication
and continuation of the (kava) medication.” We
consider this case to be unlikely.
Case 25. This case involved a 34-year-old
woman with hepatitis. According to the infor-
mation provided by the BfArM, this woman
was just taking Hypericum perforatum concomi-
tantly. There is confusion about whether this is
the same case as Case 23 and that, as recorded
by BfArM (see Appendix 2), paracetamol was
indeed a concomitant medicine. This case must
be classed as unlikely.
(6) Cases associated with an overdose of alcohol
This group included two cases: 16 and 9.
Case 16. This case involved a 33-year-old
woman with jaundice. This case is discussed at
length above because some authorities regard
this case as being probable. The woman took an
overdose of alcohol (recorded as 60 g). This
case was described in detail by Russman et al.
(2001) because the woman was deficient in CYP
2D6, which, as previously noted, may have
made her vulnerable to the mixture of kava, al-
cohol, and paracetamol (which were taken for
hangover symptoms). In these circumstances,
as stated above, this case is unlikely to be prob-
able. We believe it to be possible.
Case 9. This case is discussed in subsection 4
above.
(7) Cases not associated with other drug usage
This group included two cases: 18 and 30.
These final two cases involved men, both of
whom required liver transplants and both of
whom appeared not to have been taking other
medications. For these two cases, more details
on the medical histories is required for proper
assessment.
Case 18. This case involved a 50-year-old man
with liver necrosis and who had a liver trans-
plant. This case is discussed in some detail
above. The man took an 210–280 mg of an ace-
tone preparation per day for 1.5 months. He
also had a “moderate alcohol” intake and took
a yeast preparation. This is above the recom-
mended dose of kavalactones. He may also
have taken paracetamol (see above). This case
is unassessable .
Case 30. This case involved a 32-year-old man
with necrosis of the liver and who had a liver
transplant. He took a product containing 240
mg of kavalactones per day for 3 months and
occasionally a valerian (Valeriana officinalis)
product at night. This, too, was above the rec-
ommended dose of kavalactones. This case can-
not be evaluated fully because of lack of de-
tailed documentation regarding the man’s
medical history or the presenting disease and
so must be categorized as unassessable .
CYTOCHROME p450 METABOLISM 
OF XENOBIOTICS AND 
CYP2D6 DEFICIENCY
In most of these cases, the patients were also
taking drugs concomitantly. Assuming that the
medications were responsible for the adverse
events, and not some other factors, such as other
disease or excessive use of alcohol, it is possi-
ble that the hepatotoxicity was caused by the
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conventional drugs, by the kava, by both the
drugs and the kava, or mainly by the drugs with
the kava as a cofactor. However, in assessing
these cases, one should take into account the
apparent increased risk of adverse effects on the
liver where kavalactone concentration is en-
hanced in a product. In all cases cited by the
BfArM, the affected patients appear to have
been taking concentrated standardized prod-
ucts, which, in no way, relates to the tradi-
tional water-based or low-alcohol extracts that
have not been associated with comparable ad-
verse events. In any case, upon analysis of all
relevant factors, the number of cases cited by
the BfArM that can actually be attributed to
kava is so low that the only logical conclusion
that can be drawn is that kava has a low level
of incidence of adverse events. Interestingly,
Schmidt and Nahrstedt (2002) came to much
the same conclusion, stating that the relative
incidence of adverse events is a fraction of that
of others connected with anxiolytics, such as
benzodiazepines.
Interindividual variability in cytochrome-p450
metabolism of xenobiotics
Kava may be regarded as a possible cofactor
in some of these cases, but variable individual
responses (interindividual variability) to drugs
or herbs should also be taken into account in
these cases. Interindividual variability in drug
response is now increasingly recognized as a
major cause of adverse drug reactions. Much
of this variability is now ascribed to genetic dif-
ferences in drug absorption, disposition, me-
tabolism, or excretion. The variability that has
been most investigated and that is considered
to be of most significance is genetic polymor-
phism in drug metabolizing enzymes in the
hepatocyte. This is considered to be an adap-
tive response to environmental challenge (Wolf
and Smith, 1999) so it is not, in itself, surprising
that individuals vary and failure to metabolize
xenobiotics (“foreign” compounds, whether
these be natural or synthetic) is associated with
using medicines from natural or synthetic
sources.
Cytochrome p450 (CYP) enzymes are mixed
function microsomal mono-oxygenases that are
located on the smooth endoplasmic reticulum
throughout the body, primarily in hepatocytes
and in the wall of the small intestine. There are
12 families and a single hepatocyte can contain
a range of CYP enzymes that metabolize a
range of drugs. These CYP enzymes are re-
sponsible for phase I (oxidation, reduction, and
hydrolysis) metabolism of a wide number of
compounds and for transforming lipophilic
drugs into more polar compounds that can be
excreted by the kidneys.
Phase II of detoxification occurs if a product
conjugates in the hepatocyte cytoplasm with
the tripeptide glutathione. The resulting solu-
ble compound is excreted via the bile or the
urine. This conjugation is catalyzed by cyto-
plasmic glutathione S-transferases. Interindi-
vidual variations exist in the concentration of 
hepatocyte glutathione and in the relative con-
centration of individual glutathione S-trans-
ferases (Mannervik and Widdersten, 1995) and
in levels of other compounds that are associ-
ated with drug metabolism.
CYP2D6 deficiency
Many CYP enzymes are genetically polymor-
phic and, thus, there is marked interindividual
variation in drug metabolism (Wolf and Smith,
1999). CYP2D6 is one of the most extensively
studied genetic polymorphisms. It is thought to
cause much of the individual variations seen in
drug responses, side-effects, and drug interac-
tions (Poolsup et al., 2000). Individuals may be
poor (slow) metabolizers, intermediate, exten-
sive (fast), or ultrafast metabolizers. In a Cau-
casian population 7%–9% of individuals are ho-
mozygous deficient in CYP2D6 and are, thus,
poor metabolizers (Poolsup et al., 2000). The in-
cidence of CYP2D6 deficiency in Asian popula-
tions is 1% and it is thought that much ethnic
variation in drug response is associated with
CYP polymorphism (Poolsup et al., 2000). Drug
substrates for CYP2D6 include antidepressants,
antipsychotics, beta-blockers (e.g., propanolol
and antiarrythmics), and several antidepres-
sants (Fromm et al., 1997). A poor metabolizer
is at risk of having adverse reactions if his or her
rate of biotransformation is inadequate.
If xenobiotics are inadequately metabolized,
they may make covalent bonds with DNA, RNA,
nuclear proteins, or cytoplasmic proteins and
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breakdown of function occurs within these cells.
When this breakdown is above a certain rate, the
result of this is damage to the hepatocyte lead-
ing to centrilobular necrosis (Kaplowitz, 1997).
As noted above, Russmann et al. (2001) dis-
cussed Case 16 in detail. It is noteworthy that
the woman had restarted kava for 3 weeks af-
ter an initial course of treatment 2 months ear-
lier and then became ill 3 weeks later after an
overdose of alcohol. The woman was shown to
be CYP2D6-deficient, using phenotyping with
debrisoquine. The researchers then tested the
patient who was delineated as Case 10, which
was described by Strahl et al. (1998), and found
that she was also CYP2D6-deficient. Strahl et al.
(1998) argued that CYP2D6 deficiency is a risk
factor for hepatotoxicity that is ascribed to kava.
This finding may help to explain the lack of
hepatotoxicity as a result of kava being
recorded in the South Pacific. Wanwirolmuk et
al. (1998) tested the phenotypes of 100 persons
of pure Polynesian descent using a debriso-
quine probe and found a 0% incidence of
CYP2D6 deficiency. The researchers proposed
that, with regard to this factor, Polynesians
strongly resemble Asian populations.
As stated, many antidepressants are metab-
olized by CYP2D6 and it is likely that using an-
tidepressants with kava is not uncommon. Yet,
only one of the above cases involved antide-
pressants, which suggests that CYP2D6 defi-
ciency is more likely to be relevant than com-
petition between CYP2D6 substrates.
This finding is significant but difficult to pre-
dict because most people are unaware of their
CYP2D6 phenotype. It should be noted that
when CYP2D6 deficiency occurs, use of kava
products with enhanced kavalactones might
have implications for the affecting the liver, par-
ticularly when a concomitant orthodox medi-
cine or substantial amounts of alcohol are taken
regularly. It is proposed that such risks are likely
to be small if low-alcohol tinctures are used
within the normal therapeutic dosage range.
RECOMMENDATIONS FROM TMEC
TMEC recommends that:
(1) Products made from synthetic kavain are
synthetic drugs not herbal-medicinal prod-
ucts and should be excluded from the
analysis.
(2) None of the cases cited by the BfArM in-
volved traditionally prepared tinctures. In
the light of evidence presented above and by
Whitton et al. (Appendix 1), the safety of
concentrated standardized products made
from acetone extracts and high-alcohol con-
centrations needs reevaluation. Low-alcohol
tinctures appear to provide a safe alterna-
tive. TMEC recommends adopting extrac-
tion methods that use 25% alcohol to ensure
that the full spectrum of constituents is ex-
tracted, resulting in a substantially lower
concentration of kavalactones, thus, ensur-
ing kava’s safe use as a medicine.
(3) Consumers need to be informed that kava
products should not be taken together with
conventional medicines without the advice
of a health professional. Even more impor-
tantly, consumers need to know that kava
should not be taken without consulting a
health professional if users have estab-
lished histories of liver disease.
(4) Maximum doses for kava should be set af-
ter consultation with interested parties.
(5) Doctors, nurses, pharmacists, and other
health professionals should be adequately
informed about herbal medicines and pos-
sible herb–drug interactions (Jobst et al.,
2000).
SUMMARY
The Executive Summary issued by two Ger-
man pharmaceutical associations—Bundesver-
band der Arzneimittel–Hersteller e. V. (BAH)
and Bundesverband der Pharmazeutischen In-
dustrie e.V. (BPI) (see Appendix 3)—of their
submission to the BfArM concerning kava
stated that the causality in most of the reports
is unclear because details, such as additional
medication, patient history, and consumption
of alcohol are not given “thus not permitting a
sound evaluation of these cases.” Schmidt and
Nahrstedt (2002) noted that a number of the
cases have been reported in the literature more
than once with different data, including, as
noted above, case 28, and, in particular, that
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cases 7 and 8 are the same as are cases 26 and
27. The details of the case reports given are also
at variance with regard to case 4 in which a dif-
ferent time before onset is given and inconsis-
tencies also occur in cases 23 and 25 in which
the time before the onset of the two cases is re-
versed. These discrepancies are unsatisfactory
and undermine confidence in the accuracy and
veracity of the information provided by the
BfArM. It has also been claimed (Schmidt and
Nahrstedt, 2002) that the case reports are not
presented in accordance with European Union
guidelines for adverse-event reports.
The BfArM document is deficient in other re-
spects too. It is unclear whether the term “liver
damage” refers to the results of a liver biopsy
or to the finding of raised alanine aminotrans-
ferase (ALT) blood levels that are interpreted
as indicating damage to hepatocytes in hepa-
tocellular disease (Pagana and Pagana, 1999).
However, in light of the need for the U.K. Com-
mittee on Safety of Medicines to make an in-
formed decision on these cases, this paper en-
deavors to interpret the evidence as presented.
Unless noted otherwise, references to possible
drug-induced hepatoxocity are taken from the
British National Formulary (BNF), (March 2001).
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APPENDIX 1
Response to Reported Hepatotoxicity of High Lactone Extractions of 
Piper methysticum Forst. (Kava)
PETER WHITTON, B.Sc.,1 JULIE WHITEHOUSE, Ph.D.,2
and CHRISTINE EVANS, B.Sc., Ph.D.3
Introduction
This paper (the result of work currently in progress) was produced in response to the reports
by the German BfArM of possible hepatotoxic effects of kava (Piper methysticum Forst.) extracts
that has led to concerns regarding the safety of kava products on sale in the United Kingdom.
There have been thirty cases of hepatotoxicity reported to German and Swiss regulators including
three transplants and one death allegedly associated with the use of concentrated standardized
kava extracts.
In the Oceanic Islands of the South Pacific kava is drunk as an alternative to alcohol or for
ceremonial purposes and studies have shown, in islanders who regularly drink up to ten times
the recommended therapeutic dose, that the only recorded abnormality is a slightly raised
gamma-glutamyltransferase (Barguil, 2001).
The analysis presented in this paper, based on as-yet-unpublished research by the authors, demon-
strates the presence of glutathione in the traditional extract, which, it is postulated, may have a he-
patoprotective effect. Concentrated standardized extracts do not contain glutathione (see below).
Extraction Techniques 
In the Oceanic Islands, kava is traditionally prepared by macerating the root or root bark in
a cold water and/or coconut milk solution. However, in the manufacture of concentrated ex-
tracts either ethanol (60% and above) or acetone (60% or above) is used as a solvent to obtain
the maximum yield of kavalactones* that have been identified as the “active constituent.”
Research Data (The Result of Work in Progress)
Analysis of kava extraction in different solvents
Kava root was extracted in different solvents and analyzed by high performance liquid chro-
matography (HPLC) with diode-array detection. Different solvents were used to extract the
kavalactones and their extraction is shown in Table 1.
The extraction was carried out by reflux percolation for 1 hour for each sample of 5% w/v
Piper methysticum root. The resulting liquids then had their specific gravity and percentage of
dry extract determined by the techniques described in the British Pharmacopoeia, (1999). The
total kavalactones were measured by HPLC using an acetonitrile/water solvent gradient (Whit-
ton, 2001).
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Kavalactone standardized extracts are produced using a high acetone or ethanol concentra-
tion and are likely to contain only kavalactones and no proteins, amino acids, or sugars. 
Further analysis identified one of the other compounds in the aqueous extract and in the 25%
ethanol extract as glutathione by comparison to a reference sample obtained from Sigma-Aldrich
(Poole, Dorset, United Kingdom).
Samples of commercially available kava extracts were examined and the ratio of kavalactones
to glutathione was calculated; the results are shown below in Table 2 and Figure 1.
Importance of Glutathione in Kava Extracts
Kavalactones may cause hepatic stress, if not mediated by glutathione, and are usually me-
tabolized in the liver by enzymes called lactone hydrolases (Schmidt et al., 1999). It can also be
demonstrated in vitro that kavalactones combine with glutathione in a pH dependant reaction
by placing a mixture of kavalactones and glutathione in a test tube and adding 0.1M of sodium
hydroxide to adjust the pH to between 7 and 10. In the control solution of kavalactones alone
in this solution, no change occurs. The same process is observed when cysteine is used instead
of glutathione. This reaction is possibly nonreversible and causes the decolourization of the so-
lution. This point is important as it shows that the lactone ring structures have been opened and,
thus, changed into other as-yet-unknown compounds. The opening of the lactone ring renders
the complex water-soluble and so it can be absorbed into the gut. This may bypass the phase I
enzymatic detoxification pathway in the liver thus causing no depletion of intracellular glu-
tathione in the hepatocyte. The pH range of this reaction renders it liable to occur in the duo-
denum and so most probably occurs in vivo between the kavalactone and the cysteine moiety of
the glutathione molecule after the glutathione has been broken down to its constituent amino
acids by the gastric enzymes.
It could be that the high concentration of kavalactones introduced by concentrated standard-
ized extracts has the potential to saturate the enzymatic detoxification pathways resulting in un-
due stress on the liver. Glutathione has an essential role in the phase II conversion of kavalac-
tones into excretable waste products, and thus gluathione is relevant in excess dosage of
TABLE 1. EXTRACTION OF KAVALACTONES IN DIFFERENT SOLVENTS: SUMMARY OF
RESULTS FOR TEN SAMPLES IN EACH SOLVENT
Extract % Kavalactones in dried extract
Acetone extract 100
96% Ethanol extract 100
25% Ethanol 15
Water 2.97
TABLE 2. KAVALACTONE/GLUTATHIONE RATIOS
(RESULTS SUMMARIZED FROM TEN SAMPLES OF EACH TYPE)
Kavalactone content Glutathione content Kavalactone/glutathione 
Sample (expressed as absorbance) (expressed as absorbance) ratio
Kava standardised extract powder 4.031712e6 1.346769e3 1/0.0003
(30% kavalactones) dissolved in 
25% ethanol
82% Ethanol extraction 3.168906e5 5.3813e3 1/0.017
25% Ethanol extraction (1 part plant 1.63689e4 1.88736e4 1/1.15
to 3 parts solvent)
25% ethanol extraction (1 part plant 2.49798e4 5.1525e4 1/2.2
to 1 part solvent)
e, napierian logarithm.
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kavalactones. Glutathione is not soluble in ethanol concentrations above 50% (Merck Index, 1996).
There has been relevant work on a related group of compounds, sesquiterpene lactones. It has
been demonstrated that sesquiterpene lactones react with the sulfide group on the glutathione mol-
ecule in a reversible pH dependent reaction (Schmidt et al., 1999). The binding of the sesquiter-
pene lactones to the glutathione molecule allows for faster clearance by the lactone hydrolases pre-
sent in the hepatocytes (Schmidt et al., 2001). It has been demonstrated that oral glutathione
prevents toxicity from sesquiterpene lactones if administered at the same time (Lautermann et
al.,1995). It has also been documented that oral glutathione has to be taken at the time of inges-
tion of the kavalactones in order to potentiate the metabolism of the kavalactones.
We have shown using Acanthamoeba that, when kavalactones are added to the growth medium,
the organisms die rapidly. However, when the same experiment is carried out using a 50:50 mix-
ture of kavalactones and glutathione no cell death occurs. It was found that no cell death oc-
curred in concentrations of the glutathione/kavalactone mixture of 50 mg/mL whereas cell death
occurred using kavalactones alone at concentrations of less than 1 mg/mL. Using photomi-
croscopy, cell death was assessed via visual criteria of cell movement and cell morphology. It is
planned to repeat this procedure using hepatocyte cultures but, as the phase I and phase II path-
ways are common to most life forms, it is considered that these results could show that glu-
tathione is indeed required for the metabolism of kavalactones. 
Glutathione is present in adequate amounts in most cells in the body but some individuals
can have a genetic deficiency (Lomaestro and Malone, 1995). In these cases, high doses of kavalac-
tones will lead to rapid depletion in glutathione levels and result in free lactone exposure in the
hepatocytes and consequent tissue damage (Zheng et al., 2000). Glutathione supplementation
(taken orally) has been shown to correct the deficiency (Kidd, 1997). It is suggested that the glu-
tathione molecule may not be absorbed intact but may be broken down into its constituent amino
acids and regenerated within the hepatocyte.
It can be postulated that, as the reaction occurs in vitro without the presence of enzymes, the
binding of the sulfhydral group of common to the glutathione and the cysteine moiety to the
kavalactone may take place in the duodenum before absorption. This would allow the same pH
effect as has been seen in vitro and allow the Michael type reaction (Merck Index, 1996) to oc-
cur. It has been demonstrated in vitro (in original research undertaken by the authors) that the
addition of either glutathione or cysteine to kavalactones at a pH between 6.8 and 10.0 in an
aqueous environment leads to the solubility of the kavalactones with decolourization of the so-
lution when compared to the same process without the cysteine or glutathione.
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FIG. 1. Kavalactone and glutathione extraction (expressed as a percentage of dry extract) against ethanol percentage
in solvent.
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The decolourization strongly suggests that the lactone ring has been opened in this reaction
thus making the resultant compound water-soluble. This means that this reaction, which takes
place without the presence of enzymes, can occur in the duodenum. This would lead to the ab-
sorption of the complex of cysteine/glutathione and kavalactone into the hepatocyte without
putting stress on the phase I pathway and so no depletion of intracellular glutathione would
take place. This suggests that the liver was able to cope with oxidative stress from other sources
with no interference from the kava.
Previous experiments have been conducted with oral glutathione and acetaminophen (parac-
etamol) where no non-enzymatic pathway has been observed. These findings are readily ex-
plained by the different structural formulae of these compounds (Fig. 2).
It can be demonstrated that that the cysteine moiety of the glutathione molecule binds via the
Michael reaction to the oxygen atom in the lactone ring with the kavalactones. This opens the
ring and leaves the double-bonded oxygen unit intact. As mentioned previously, the resulting
conjugate is water soluble because of the presence of the thiol group from the cysteine. In the
case of acetaminophen (paracetamol), this reaction cannot take place without the presence of the
phase I enzymes as the molecule is cleaved at the amine (nitrogen) group in alkaline conditions
(as the authors have demonstrated). This is quite possibly the reason why large doses (ten to
fifty times the therapeutic dose of 60–120 mg per day) of the traditional kava extract have been
shown not to cause hepatic damage whereas the standardized concentrated extract has been as-
sociated with these cases.
Another strong piece of evidence that the kavalactones may be moderated by other compo-
nents in traditional use comes from the epidemiologic studies carried out in Arnhem Land in
FIG. 2. Chemical stuctures of (A) glutathione, (B) kavalactones, (C) acetaminophen, and (D) cysteine.
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the Northern Territories in Australia. These preliminary studies have found no evidence of liver
damage in individuals who habitually ingest kava extracts equivalent to between ten and fifty
times the daily therapeutic dose (60–120 mg) of kavalactones per day.*
Summary
Kavalactones are normally metabolized by lactone hydrolases, which are enhanced by the
presence of glutathione.
Glutathione naturally occurs in kava in a 1:1 ratio with kavalactones and is likely to reduce
the likelihood of potential lactone toxicity. In contrast to the traditional crude extract, stan-
dardized extracts contain no glutathione while containing up to 30 times the kavalactone con-
centration.
It appears that the high kavalactone in concentrated standardized extracts may deplete the re-
serves of glutathione in the hepatocytes which could result in liver damage. It would therefore
seem prudent to limit the organic solvent level in the extraction of kava to 25% ethanol in order
to ensure the preservation of the hepatoprotective effect of the glutathione. Tinctures made with
25% ethanol would appear to be safe as a result of this synergistic effect of the glutathione and
kavalactones. 
Conclusions
Traditional preparations have had many years of safe usage (Norton and Ruse, 1994) and tox-
icity has only been reported in Europe with concentrated standardized extracts (Escher et al.,
2001).
This paper argues that there are significant differences between concentrated extracts and those
produced by traditional methods that maintain a satisfactory ratio between glutathione and
kavalactones. In traditional extracts, ratios of at least 1:1 kavalactone:glutathione should provide
a safe product with hepatoprotective action. It would appear that glutathione has an important
synergistic action in protecting the liver from potential lactone toxicity.
This study suggests that standardized herbal extracts which do not contain all components of
the traditional plant extract may have a potential to induce hepatotoxicity in susceptible people
(e.g., those taking concomitant orthodox medicines). It is proposed that tinctures manufactured
using a traditional cold-maceration process (in 25% ethanol and 75% water) that is more nearly
approximate to traditional water or coconut milk extracts, or raw plant material, are safe in nor-
mal subjects.
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APPENDIX 3
Executive Summary Issued January 18, 2002, by the Bundesverband der
Arzneimittel–Hersteller e. V. (BAH) and Bundesverband der Pharmazeutischen 
Industrie e.V. (BPI): Comments of BAH/BPI on the BfArM Letter of November 8, 2001, 
on Kava- and Kavain-Containing Medicinal Products
Executive Summary
On December 18, 2001, the BAH and BPI, the German pharmaceutical trade associations, sub-
mitted a statement to BfArM, the German health authority, on behalf of German kava manu-
facturers, subsequent to a letter from BfArM of November 8. 2001. The industry’s statement
comes to the conclusion that the presented data on the benefit/risk assessment of kava- and
kavain-containing medicinal products do not justify the withdrawal of marketing authorisations.
The companies already included risk information in their package leaflets and expert informa-
tion at their own responsibility and consider control of patients applying kava products by a
physician as an appropriate means of ensuring safe usage.
In particular, in most of the reported cases, the causality between kava intake and liver reac-
tions is not clear because further medication was used which might have caused liver toxicity.
In many cases, detailed information on the patients’ history, co-medication, consumption of al-
cohol and further particulars are missing, thus not permitting a sound evaluation of these cases.
Regarding clinical efficacy, there are placebo-controlled and reference-controlled clinical stud-
ies as well as open studies which demonstrate an improvement of symptoms in conditions of
nervous anxiety, stress and restlessness.
Data on the Risk Assessment
The report published by Kraft et al. (2001) describes liver failure in a 60-year-old female patient
who took a kava preparation in an amount up to four times of the recommended daily dose. Liver
transplantation was required. Due to further medication containing piretanid and etilefrin which
might have caused liver-related side effects, kava is unlikely to be the only cause of the side effect.
The case report published by Brauer et al. (2001) describes liver failure in a 22-year old female
patient. Liver transplantation was required. Since the patient also took rizatriptan and oral con-
traceptives, which might have liver-related side effects, kava is unlikely to be the only cause of
the side effect.
The case report published by Sass et al. (2001) describes a 50-year old female patient who took
kava for seven months in a daily dose of 60 mg kavapyrones. She experienced a hepatic coma;
liver transplantation was required. Glimepirid and estradiol were used as co-medication. A
causal connection between the liver effect and kava intake cannot definitely be excluded. How-
ever, contribution by the co-medication to the side effect seems possible.
A further case report on kava (Strahl et al., 1998) describes a necrotising hepatitis in a 39-year
old female patient with positive re-exposition. During the first application of the kava product,
an oral contraceptive as well as paroxetin were used. A causal relationship with kava cannot be
excluded, but the patient’s history and a potential pre-existing liver damage must be taken into
account. In addition, the kava preparation used was not identified by the physician.
In additional reports from Switzerland, Escher et al. (2001) and Stoller, (2000) describe two
cases: a liver transplantation in a 50-year old female patient using also evening primrose oil, a
yeast preparation and paracetamol as well as liver symptoms in a 33-year old patient who also
applied propyphenazon and paracetamol and consumed alcohol.
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Most of the other case reports (not quoted by BfArM) cannot be assessed since essential data
are missing, or they have to be evaluated as “improbable” or “questionable.”
Data on the Benefit Assessment
According to a meta-analysis performed by Pittler and Ernst (2001), therapeutic equivalence
of kava and synthetic anxiolytics can be assumed.
For an extract prepared with acetone as [a] solvent, there are seven randomised placebo-con-
trolled double blind studies as well as one randomised reference-controlled double blind study
performed between 1991 and 2001. They demonstrate the efficacy of the kava extract in condi-
tions of nervous anxiety, stress and restlessness.
On various ethanolic extracts, the following data are available:
 A three-arm double-blind clinical study in 127 patients versus opipramol and buspirone in
order to prove efficacy in general conditions of nervous anxiety
 A non-interventional study in 1187 patients confirming these results and demonstrating good
tolerability
 A pharmacodynamic study versus bromazepam and placebo showing relaxing and anxiolytic
effects of a kava extract as well as better tolerability than bromazepam
 An in-vivo experiment (elevated plus maze test in rats) showing a remarkable anxiolytic ef-
fect of a kava extract comparable to that of diazepam
 A randomised, controlled, double-blind study in 69 patients demonstrating improvement of
the total Hamilton Anxiety Scale score as well as for the score for [psychologic] and somatic
anxiety at a dose of 200 mg kavapyrones daily
 A study demonstrating a tranquillising effect (comparable to benzodiazepines) in conditions
of anxiety prior to medical surgery
 A non-interventional study in 3338 patients demonstrating a remarkable decrease in symp-
toms of anxiety after an average duration of therapy of 2.5 months
 An observational study in 52 patients showing a decrease of anxiety-related symptoms
 An observational study including 30 patients with psycho-somatic complaints which demon-
strated improvement
 Further experiments with a lower number of patients as well as a non-interventional study
currently being performed including 131 patients.
As a result of their proven clinical efficacy, kava preparations were included in the draft pos-
itive list issued by the German ministry of health in July 2001. According to this draft list, kava
products are reimbursable by the state health insurance like chemical substances used in this in-
dication field.*
Conclusion
Conditions of nervous anxiety, stress and restlessness must be regarded as wide-spread dis-
orders which, without treatment, might have severe [psychologic] and social consequences and
for this reason require medical treatment. In case kava products are withdrawn from the mar-
ket, only chemical substances would be available as therapeutic alternatives, e.g. benzodi-
azepines, anxiolytics, anti-depressants, neuroleptics, et cetera. Yet, all these substances have
*Note added: An indication field is a range of indications, for example, anxiety, for reimbursement under the state
medical system in Germany.
many side-effects, including liver toxicity. Benzodiazepines as an alternative have a high po-
tential of addiction.
Available data on the benefit–risk assessment of kava and kava-containing medicinal prod-
ucts do not justify the withdrawal of the respective marketing authorisations. Inform[ing] . . .
the patient by package leaflets as well as expert information and [supervision] of patients by a
physician are regarded as an appropriate means [using kava].
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